-- 阳光湖制药(港交所代码:6887)周三向港交所提交的文件显示,港交所已批准其香港股份全面流通申请。 周四早盘交易中,该制药公司的股价上涨近1%。 此次批准涵盖约2.084亿股香港本地股份转换为香港上市股份。 转换后的股份约占公司已发行股本的36.1%。 转换完成后,香港上市股份将占公司股本的约55.7%,高于转换前的19.6%。
Related Articles
ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1
ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.
Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond
Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.
Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates
Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.